Canadian Cancer Trials Group Bulletins


Recent Publications

Canadian Cancer Trials Group HD.7 (ECOG 2496) - A Randomized Phase III Trial of ABVD versus Stanford V with or without Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease

The authors found that there was no significant difference in the overall response rate between the two arms and concluded that ABVD remains the standard of care for patients with advanced Hodgkin lymphoma.

Gordon LI, Hong F, Fisher RI, Bartlett NL, Connors JM, Gascoyne RD, Wagner H, Stiff PJ, Cheson BD, Gospodarowicz M, Advani R, Kahl BS, Friedberg JW, Blum KA, Habermann TM, Tuscano JM, Hoppe RT, Horning SJ. Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496) (ONLINE). J Clin Oncol 2012.

Accompanying Editorial:


Canadian Cancer Trials Group MY.11 - A Randomized Phase II Dose Finding Study of Lenalidomide and Melphalan in Patients with Previously Untreated Multiple Myeloma

The authors found that combining lenalidomide plus melphalan without prednisone is associated with substantial hematologic toxicity that precludes cyclical administration of adequate drug doses.

White DJ, Bahlis NJ, Marcellus DC, Andrew Belch, Stewart AK, Chen C, Kovacs MJ, Macdonald DA, Reece DE, Reiman T, Harnett E, Meyer RM, Chapman J-AW, Couban S. Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial. Clinical Lymphoma Myeloma and Leukemia.

Meyer RM, Hoppe RT. Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy. Blood 2012 120(23): 4488-4495.